Progress in the treatment of relapsed/refractory follicular lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 16-19, 2022.
Article
em Zh
| WPRIM
| ID: wpr-929725
Biblioteca responsável:
WPRO
ABSTRACT
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. Although patients with FL generally have a good prognosis, the treatment of relapsed/refractory FL remains a challenge. The 63rd American Society of Hematology (ASH) Annual Meeting announced the latest updates on relapsed/refractory FL, including the usage of targeted therapy, bio-specific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy. This article provides an overview of the updates in combination with the reports presented at the ASH Annual Meeting.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2022
Tipo de documento:
Article